First report in Peru on direct-acting antiviral therapy for chronic hepatitis C in HIV-positive patients

Descripción del Articulo

Objective: To present the clinical experience with direct-acting antivirals (DAAs) for chronic hepatitis C in HIV-positive patients. Materials and methods: Longitudinal and prospective case series of HIV-positive patients treated with DAAs for chronic hepatitis C between May 2019 and April 2020 at t...

Descripción completa

Detalles Bibliográficos
Autores: Collins, Jaime A., Chamorro Chirinos, Elena Rocio, Loyola Salvatierra, Fiorella Vanessa, de SIDA, Grupo de estudio
Formato: artículo
Fecha de Publicación:2022
Institución:Sociedad de Gastroenterología del Perú
Repositorio:Revista de Gastroenterología del Perú
Lenguaje:español
OAI Identifier:oai:ojs.revistagastroperu.com:article/1291
Enlace del recurso:http://www.revistagastroperu.com/index.php/rgp/article/view/1291
Nivel de acceso:acceso abierto
Materia:Antivirals
hepatitis C
chronic
HIV
Peru
antivirales
hepatitis C crónica
VIH
Perú (Fuente
DeCS Bireme)
Descripción
Sumario:Objective: To present the clinical experience with direct-acting antivirals (DAAs) for chronic hepatitis C in HIV-positive patients. Materials and methods: Longitudinal and prospective case series of HIV-positive patients treated with DAAs for chronic hepatitis C between May 2019 and April 2020 at the Infectious Diseases Service of Hospital G. Almenara, EsSalud. The primary outcome was sustained virologic response to hepatitis C virus (HCV) 12 weeks after completion of DAA therapy. Secondary outcomes were tolerability and safety. Results: Ten patients were included in the study, two were women (20%). Two patients had cirrhosis (20%). All patients had suppressed HIV viral load prior to DAA therapy. Patients received a 12-week regimen based on sofosbuvir: one with daclatasvir separately, and the remaining nine with velpatasvir combined in a single tablet per day. The sustained virological response of HCV was evaluable nine cases. In these, the HCV viral load was undetectable. No occurrences were recorded regarding tolerability and safety during therapy with the indicated DAAs. Conclusions: This present investigation is the first clinical experience in Peru with DAAs for chronic hepatitis C in HIV-positive patients. Virologic response, tolerability, and safety again njunction or in combination with sofosbuvir, were optimal in the case series presented.
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).